NEW
Stock Screener with Intrinsic Value
Bristol-Myers Squibb Company (BMY)
Last Price$56.3(0.2%)
Market Cap$114.2B
WACC
5.6%
Cost of Equity
7.8%
Cost of Debt
0.7%
Debt to Equity
45.0%
Beta
0.7
Stock quality
6/10
Good
BMY WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
BMY Cost of Equity
Crunching data... Almost there!
BMY vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Bristol-Myers Squibb CompanyBMY
5.6%
(2.5%)
30.6%
17.8%
Median Peer Set
6.7%
1.4%
(15.9%)
15.4%
Eli Lilly and CompanyLLY
7.5%
19.6%
(15.9%)
15.4%
Johnson & JohnsonJNJ
7.2%
6.5%
102.3%
41.3%
Merck & Co., Inc.MRK
6.9%
1.4%
(97.6%)
0.6%
Novartis AGNVS
6.8%
(10.0%)
124.1%
31.8%
Gilead Sciences, Inc.GILD
6.7%
(0.6%)
24.0%
20.9%
AbbVie Inc.ABBV
6.5%
(6.4%)
(58.9%)
9.0%
Amgen Inc.AMGN
5.9%
7.1%
3.1%
23.8%
Pfizer Inc.PFE
5.8%
(41.7%)
(93.2%)
3.6%
SanofiSNY
negative
4.1%
(33.9%)
11.7%
Explore more intrinsic value tools hub for BMY
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Bristol-Myers Squibb Company's discount rate as of Jan 17, 2025?
As of Jan 17, 2025, Bristol-Myers Squibb Company's discount rate is 5.62%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Bristol-Myers Squibb Company's capital structure and risk profile.
What is Bristol-Myers Squibb Company's weighted average cost of capital (WACC)?
Bristol-Myers Squibb Company's WACC as of Jan 17, 2025, is 5.62%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Bristol-Myers Squibb Company's cost of equity?
Bristol-Myers Squibb Company's cost of equity is 7.8%, as of Jan 17, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.